Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cypherpunk Technologies Inc. (CYPH) vs ARS Pharmaceuticals, Inc. (SPRY)

Cypherpunk Technologies Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Cypherpunk Technologies Inc. and ARS Pharmaceuticals, Inc. are of similar size ($440.8M and $412.7M). ARS Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Cypherpunk Technologies Inc. trades at 7.0×. ARS Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 4.08% against 0.00%. Cypherpunk Technologies Inc. has the higher net margin (0.00% vs −184.3%) and the higher return on invested capital (−8.44% vs −335.7%). Across the 17 metrics below, Cypherpunk Technologies Inc. leads on 13 and ARS Pharmaceuticals, Inc. on 4.

Valuation

Metric CYPH SPRY Biotechnology median
P/E 6.98 n/m 7.88
P/S 506.29 3.47 11.47
P/B 5.45 32.38 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 501.20 3.70 10.73
Earnings yield 14.32% (53.43%) (28.84%)
Free cash flow yield (2.77%) (52.35%) (23.03%)

Profitability

Metric CYPH SPRY Biotechnology median
Gross margin 0.00% 71.37% 65.16%
Operating margin 0.00% (184.96%) 0.00%
Net margin 0.00% (184.26%) 0.00%
Free cash flow margin 0.00% (167.97%) 0.00%
Return on equity (1.21%) (210.37%) (57.72%)
Return on assets (1.08%) (76.54%) (49.22%)
Return on invested capital (8.44%) (335.65%) 0.00%

Growth

Metric CYPH SPRY Biotechnology median
Revenue growth (TTM) 0.00% 4.08% 5.64%
EPS growth (last fiscal year) 103.87% (2,275.00%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CYPH SPRY Biotechnology median
Debt to equity 0.00 13.72 0.00
Current ratio 79.19 3.48 4.73
Net debt to EBITDA 0.34 0.42 0.96

Dividend

Metric CYPH SPRY Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CYPH SPRY Biotechnology median
Market cap 440.76m 412.71m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack